Weber on Oncology

• Melanoma Updates From ASCO 2023: PD-1 and LAG-3   Jeffrey S. Weber, MD, PhD, discusses updates related to melanoma practice and care from ASCO 2023.
  Medscape Oncology, October 24, 2023
• Society for Melanoma Research 2022: Adjuvant and TIL Therapy   Jeffrey S. Weber, MD, PhD, discusses abstracts presented at the recent Society for Melanoma Research meeting in Edinburgh, Scotland.
  Medscape Oncology, March 03, 2023
• Neoantigen Vaccine With Pembrolizumab Has Clear Benefit in Melanoma   Jeffrey S. Weber, MD, PhD, discusses recently released data on a new antigen vaccine with pembrolizumab.
  Medscape Oncology, March 01, 2023
• AACR 2022 New Data for Melanoma Patients Who Progress After PD-1 Blockade   Dr Jeffrey Weber discusses potential new approaches to managing melanoma patients who progress after anti-PD-1 agents.
  Medscape Oncology, December 08, 2022
• ESMO 2021 Melanoma Update: 3 Important Trials from ESMO 2021   Dr Jeffrey Weber discusses recent melanoma studies presented at ESMO 2021.
  Medscape Oncology, December 22, 2021
• ASCO 2021 New Long-term Melanoma Data 'Clearly Favor' IPI/NIVO   Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021.
  Medscape Oncology, August 03, 2021
• ASCO 2021 What's Next After Anti-PD-1 Therapy for Melanoma Fails?   Dr Jeffrey Weber describes two studies with encouraging results for patients with advanced melanoma that has not responded to anti-PD-1 and other immunotherapies.
  Medscape Oncology, July 29, 2021
• ASCO 2021 NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma   ASCO studies validate dual LAG-3 and PD-1 inhibition in advanced melanoma, with good tolerability profiles, says Jeffrey Weber.
  Medscape Oncology, July 01, 2021
• Studies Back Neoadjuvant Strategies for Melanoma   Two analyses of neoadjuvant immunotherapy support more rigorous study with RCTs of neoadjuvant vs adjuvant strategies for melanoma, says Dr Weber.
  Medscape Oncology, March 24, 2021
• 'Impressive Results' From Stage III Melanoma Studies: ASCO 2020   Dr Jeffrey Weber describes three adjuvant and/or neoadjuvant studies in stage III melanoma that piqued his interest at this year's American Society of Clinical Oncology virtual meeting.
  Medscape Oncology, August 25, 2020
• Re-treating Melanoma After PD-1 Blockade Shows Good Response   In patients who received single-agent PD-1 blockade for melanoma, how effective is second-line therapy? A recent study addresses this important question.
  Medscape Oncology, July 22, 2020
• Searching for Biomarkers to Better Guide Melanoma Therapy   Dr Jeffrey Weber explores the phase 3 COMBI-AD melanoma trial. Could tumor mutational burden alone or in combination with interferon gamma gene signature be a prognostic factor?
  Medscape Oncology, June 03, 2020
• BRAF/MEK Combo Yields 'Impressive' 5-Year Survival in Melanoma   Roughly one third of advanced melanoma patients who start out with dabrafenib plus trametinib will do well long-term, Dr Weber reports.
  Medscape Oncology, September 16, 2019
• Response to Initial IO Treatment Predicts Melanoma Outcomes   Patients with a brisk initial response to PD-1 antibody treatment may need only one dose of treatment, says Dr Weber.
  Medscape Oncology, September 11, 2019
• CheckMate 204 Update: Practice-Changing for Brain Metastases?   New data show that ipilimumab plus nivolumab can produce a long-term response in patients with melanoma and brain metastases, says Dr Jeffrey Weber.
  Medscape Oncology, September 09, 2019
  6
• Improved Safety Profile With 'Flip Dose' Nivo/Ipi Regimen   Dr Jeffrey Weber discusses results from the CheckMate 511 trial, which demonstrated decreased adverse events with a revised dosing approach.
  Medscape Oncology, July 05, 2019
• Does Neoadjuvant pCR in Melanoma Predict Better Outcomes?   Jeffrey Weber discusses recent trials investigating neoadjuvant combination immunotherapy in patients with melanoma.
  Medscape Oncology, April 16, 2019
• In Melanoma, IO plus HDAC Inhibitor Yields 'Impressive Results'   Jeffrey Weber comments on a promising approach for heavily pretreated melanoma patients that was recently presented at the 2019 AACR annual meeting.
  Medscape Oncology, April 11, 2019
  1
• CheckMate 204: 'Practice-Changing' for Metastatic Melanoma   The ipilimumab plus nivolumab combination gives patients a reasonable chance of CNS tumor regression, thus not requiring radiation, according to Jeffrey Weber.
  Medscape Oncology, April 03, 2019
  1
• 'Optimistic' Longer-term Outcomes for Metastatic Melanoma   Targeted therapy and immunotherapy are showing promising longer-term outcomes in metastatic melanoma. Dr Weber reviews two new studies.
  Medscape Oncology, March 21, 2019